Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist’s Perspective
Dana Balitzer, Sanjay Kakar – 4 May 2021
Pathology of Hepatic Iron Overload
Marcela A. Salomao – 4 May 2021
Vascular Neoplasms of the Liver
Jingmei Lin, Maria Westerhoff – 4 May 2021
Hepatocellular Adenoma and Focal Nodular Hyperplasia
Taofic Mounajjed – 4 May 2021
Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration
Kiran V.K. Koelfat, Kim M.C. Mierlo, Toine M. Lodewick, Johanne G. Bloemen, Gregory Kroft, Iakovos Amygdalos, Ulf P. Neumann, Cornelis H.C. Dejong, Peter L.M. Jansen, Steven W.M. Olde Damink, Frank G. Schaap – 4 May 2021 – The involvement of bile salt–fibroblast growth factor 19 (FGF19) signaling in human liver regeneration (LR) is not well studied. Therefore, we studied aspects of bile salt–FGF19 signaling shortly after liver resection in patients.
Histological Patterns of Hepatitis and Cholangitis
Raouf E. Nakhleh – 4 May 2021
Pathology of Cholangiocarcinoma and Combined Hepatocellular‐Cholangiocarcinoma
Murli Krishna – 4 May 2021
Pathology of Fibropolycystic Liver Diseases
Jason Lewis – 4 May 2021
Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis
Patrick Marquardt, Po‐Hong Liu, Joshua Immergluck, Jocelyn Olivares, Ana Arroyo, Nicole E. Rich, Neehar D. Parikh, Adam C. Yopp, Amit G. Singal – 3 May 2021 – Professional society guidelines recommend semiannual screening for hepatocellular carcinoma (HCC) in patients with cirrhosis; however, studies suggest underuse of screening in clinical practice. Our study’s aim was to characterize reasons for HCC screening underuse among patients with cirrhosis. We conducted a retrospective cohort study of patients with cirrhosis diagnosed with HCC in two large health systems from 2011 to 2019.
Frailty and Sarcopenia in Acute‐on‐Chronic Liver Failure
Lorena Puchades Renau, Julia Herreras López, Maria Àngels Cebrià i Iranzo, Natalia Cezón Serrano, Tommaso Di Maira, Marina Berenguer – 3 May 2021 – In patients with cirrhosis, sarcopenia is a critical reduction in skeletal muscle mass and frailty represents a status of global physical dysfunction caused by under nutrition, muscle wasting, and functional impairment. Both are prevalent conditions in liver transplant candidates and have shown to be independent predictors of adverse outcome.